Real-world safety and effectiveness of ofatumumab in multiple sclerosis: A clinic-based study in Australia
{{output}}
Background: Monoclonal antibodies that target the CD20 antigen and cause B-cell depletion have proven to be a highly effective treatment strategy in relapsing-remitting MS (RRMS). Ofatumumab, the first fully human anti-CD20 monoc... ...
